Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders

  • Voyager Therapeutics Inc VYGR has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody.
  • The results will be presented at the American Society of Gene and Cell Therapy.
  • Data demonstrate durable expression in the central nervous system (CNS). They may represent a new single-dose therapeutic strategy for treating various tauopathies such as progressive supranuclear palsy, frontal, temporal dementia, and Alzheimer's disease.
  • Voyager has developed modular antibody vectorization cassettes consisting of an adeno-associated virus (AAV) vector and a transgene encoding anti-tau monoclonal full-length antibodies.
  • Following intravenous administration and transduction of target cells in the brain, the expressed antibodies are functionally reconstituted and subsequentially secreted into the parenchyma.
  • Anti-tau antibody expression was detected as early as two days post-dose, reaching maximum levels at day 7, with durable expression extending to 28 days.
  • Dose-dependent decreases in the levels of pathological tau and neurofibrillary tangles were observed, resulting in up to 59% reduction in tau pathology.
  • Price Action: VYGR shares are trading 2.5% higher at $4.51 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralAlzheimer's diseasecentral nervous system disordersdementia
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!